Testing a new treatment for moderate kidney disease

Plain-English translation of NCT06721143 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This clinical trial is testing a medication called to see if it can help people with Stage 3 chronic kidney disease — a moderate level of kidney function decline. Researchers want to learn whether this new treatment is safe, well-tolerated, and can reduce symptoms or slow the disease's progression. Half of participants will receive the actual medication, and half will receive a placebo (a look-alike substance with no active drug) so researchers can see if the medication truly works.

Stage 3 chronic kidney disease affects millions of people, and while current treatments help, many patients still experience disease progression. This trial is testing whether this new treatment could offer additional benefit to patients already on standard kidney disease medications.

Do you qualify?

You likely qualify if…

you are between 35 and 75 years old
you have been diagnosed with Stage 3 chronic kidney disease with confirmed kidney function and protein levels in a specific range
you have been on maximum tolerated doses of standard kidney disease medications (like ACE inhibitors, ARBs, or SGLT2 inhibitors) for at least 3 months with stable dosing
you are willing and able to attend clinic visits and follow the study schedule over 6 to 24 months
if you are female, you are willing to use two forms of FDA-approved birth control during the study and are not breastfeeding

You likely don't qualify if…

you have had a kidney transplant or any other organ transplant (including stem cell transplant) in the past
you have had a heart attack, stroke, or recent hospitalization for heart failure in the past 12 weeks
you have very high blood pressure (160/100 mmHg or higher) or very low blood pressure (below 90 systolic) at screening
you have very severe kidney protein loss (proteinuria greater than 5000) or very low blood albumin levels (below 2.5 g/dL)
you have a kidney transplant scheduled within the next 6 months

What participation looks like

You will receive two intravenous infusions of either the medication or placebo — one on Day 0 and another on Day 4. You will also receive oral vitamins both at the clinic and to take at home for 90 days. Over the next 6 to 24 months, you will visit the clinic at least 9 times (up to 12 times) for checkups, blood tests, and urine tests to monitor how you respond to the treatment and check for any side effects.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Testing a new treatment for moderate kidney disease

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)